Celltrend offers a new test for autoantibodies involved in Small fiber neuropathy:
Small Fiber Neuropathy (SFN)
Small Fiber Neuropathy (SFN) is a subtype of neuropathy that is characterized by the selective involvement of non-myelinated or thinly-myelinated sensory fibers is marked. Its pathogenesis includes a wide range of immune-mediated, metabolic, toxic, hereditary and genetic disorders. SFN has been described in connection with Sjögren’s syndrome, celiac disease, systemic lupus erythematosus, rheumatoid arthritis, diabetes mellitus type 1, inflammatory bowel disease, sarcoidosis and paraneoplastic syndrome. Some data also suggest an association with Hashimoto’s thyroiditis. Clinical symptoms of SFN can manifest as isolated sensory disorders as well as isolated autonomic disorders.
Intravenous immunoglobulin therapy (IVIG) showed a significant effect in treating patients with autoimmune mediated SFN in two large retrospective studies with comparable response rates (77% and 83% of patients).
Autoantibodies against fibroblast growth factor receptor-3 (FGFR3-IgG) and tri-sulfate heparin di-saccharide (TSHDS-IgM) are elevated in SFN. A clinical study is currently evaluating the efficacy of IVIG administration in FGFR3-Ab and TSHDS-Ab positive patients.
FGFR3 auto-antibodies
TSHDS auto-antibodies
POISers should investigate their own individual immune/hormone profile in my opinion.
